Norucholic Acid

Summary

Norucholic Acid (CHEMBL1254990) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including sclerosing cholangitis and metabolic dysfunction-associated steatohepatitis.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 2 conditions
• Clinical trials: 3
• Chemistry: 378.5 Da · C23H38O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1254990
Name	Norucholic Acid
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	192254
Molecular formula	C23H38O4
Molecular weight	378.5
InChIKey	QYYDXDSPYPOWRO-JHMCBHKWSA-N

SMILES: C[C@H](CC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C

IUPAC name: (3R)-3-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]butanoic acid

Also known as: Acide norucholique, Acido norucolico, Nor-ursodeoxycholic acid, Norucholic acid, Norursodeoxycholic acid, NORUCHOLIC ACID

Patent coverage: 50 distinct patent families (148 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: G-protein coupled bile acid receptor 1.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
sclerosing cholangitis	3	MONDO:0018646	EFO:0004268
metabolic dysfunction-associated steatohepatitis	2	MONDO:0007027	EFO:1001249

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03872921	PHASE3	ACTIVE_NOT_RECRUITING	norUrsodeoxycholic Acid vs Placebo in PSC
NCT06886360	PHASE3	NOT_YET_RECRUITING	Study with Norucholic Acid Tablets in Patients with Primary Sclerosing Cholangitis (PSC)
NCT05083390	PHASE2	UNKNOWN	Norursodeoxycholic Acid vs. Placebo in NASH

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).